Document:

EX-10.16

 Exhibit 10.16 

SEPARATION AND RELEASE AGREEMENT 

This Separation and Release Agreement (this “Agreement”), delivered
December 21, 2017, confirms the following understandings and agreements between Melinta Therapeutics, Inc., a Delaware corporation (the “Company”) and John Temperato (hereinafter referred to as
“you” or “your”). 
 In consideration of the promises set
forth herein, you and the Company agree as follows: 
 1.    Opportunity for Review; Acceptance. You have until
February 16, 2018 (the “Review Period”), to review and consider this Agreement and the disclosure information provided pursuant to the Older Workers Benefit Protection Act (attached
hereto as Exhibit A). To accept this Agreement, and the terms and conditions contained herein, prior to the expiration of the Review Period, you must execute and date this Agreement where indicated below and return the executed copy of this
Agreement to the Company’s Vice President, Human Resources, Suzie Paulson (the “Company Representative”) by mail at c/o Melinta Therapeutics, 6320 Quadrangle Drive, Suite 360, Chapel Hill, North Carolina
27517, Attention: Suzie Paulson, or by email at spaulson@melinta.com. You acknowledge that, to the extent there are changes made to the terms of this Agreement, whether they are material or immaterial, the Review Period is not recommenced.
Notwithstanding anything contained herein to the contrary, this Agreement will not become effective or enforceable for a period of seven (7) calendar days following the date of your execution of this Agreement (the “Revocation
Period”), during which time you may revoke your acceptance of this Agreement by notifying the Company Representative, in writing, to the address specified above. To be effective, such revocation must
be received by the Company Representative no later than 5:00 p.m. Eastern Time on the seventh (7th) calendar day following your execution of this Agreement. Provided that this Agreement is
executed during the Review Period, and you do not revoke it during the Revocation Period, the eighth (8th) day following the date on which this Agreement is executed and delivered to the Company
Representative shall be its effective date (the “Effective Date”). In the event that you fail to execute and deliver this Agreement prior to the expiration of the Review Period, or if you
otherwise revoke this Agreement during the Revocation Period, this Agreement will be null and void and of no effect, and the Company will have no obligations hereunder. 
  

	 	2.	Employment Status; Accrued Benefits; and Separation Payments. 

(a)    Employment Status. You acknowledge and agree that your employment with the Company and its direct and
indirect parent(s), subsidiaries, and affiliates (collectively, with the Company, the “Company Group”), will terminate effective as of the close of business on January 2, 2018 (the
“Separation Date”), and after the Separation Date, you will not represent yourself as being an employee, officer, agent, or representative of the Company or any other member of the Company
Group. You hereby confirm your resignations from all offices, directorships, trusteeships, committee memberships and fiduciary and other capacities held with, or on behalf of, the Company Group effective as of the Separation Date and your execution
of this Agreement will be deemed the grant by you to the officers of the Company of a limited power of attorney to sign in your name and on your behalf any such documentation as may be required to be executed solely for the limited purposes of
effectuating such resignations. You agree that within five (5) business days following the Separation Date, you will update your accounts or profiles on any social media platform (including, but not limited to, Facebook, Twitter, MySpace or
LinkedIn) to reflect that you are no longer actively employed by or affiliated with the Company. 
 (b)    Accrued
Benefits. The Separation Date shall be the termination date of your employment for purposes of participation in and coverage under all benefit plans and programs sponsored by or through the Company and any other member of the Company Group,
except as otherwise provided herein. You will be paid for (i) all of your earned but unpaid salary through the Separation Date and, to the extent payable pursuant to the Company’s policies, your accrued but unused vacation as of the
Separation Date, in each case, on or prior to the Company’s next regularly scheduled payroll date on or following the Separation 

 
Date, or earlier to the extent otherwise required by applicable law, and (ii) any business expenses incurred prior to the Separation Date and properly submitted in accordance with the
Company’s policies and procedures within ten (10) days of the Separation Date. In addition, you will be entitled to continued medical and health benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985
(“COBRA”), and additional information concerning such benefits will be provided to you under separate cover following the Separation Date. 

(c)    Separation Payments and Benefits. In consideration of your release and waiver of claims set forth in
paragraph 3 below, subject to your execution, delivery and non-revocation of this Agreement and continued compliance with this Agreement, including but not limited to, paragraph 11 hereof, the Company will
provide you with the following separation benefits (the “Consideration”): 

(i)    Base Salary Continuation. An amount equal to twelve (12) months of your annual base
salary, payable in equal installments in accordance with the Company’s regular payroll practices over a period of twelve (12) months, commencing on the first regularly scheduled payroll date following the Separation Date; 

(ii)    COBRA Premiums. If you elect continuing group medical coverage pursuant to COBRA,
reimbursement of the employer portion of the premium costs of such continuation coverage (consistent with the Company’s policy for active employees) until the earlier of (x) the end of the twelfth (12th) month following the Separation Date, or (y) the date you are eligible for coverage under another group health plan, subject to the terms of the Company’s plan and applicable law. You
agree to notify the Company of your eligibility for coverage under another group health plan during the period you are entitled to payments under this paragraph within ten (10) days of such eligibility; and 

(iii)    Pro-rated Annual Bonus. A lump sum cash payment
equal to $208,068.75, representing the pro-rata portion of the annual bonus that you would otherwise have earned in respect of the 2017 fiscal year based on the number of months of completed employment up to
the Separation Date, such amount to be paid at the same time it would otherwise be paid to you had no termination occurred, but in no event later than March 1, 2018. 

(d)    Deferral of Payments. Notwithstanding the foregoing, in the event that any payment otherwise scheduled to
occur prior to the Effective Date, but for the condition on executing this Agreement, shall not be made until the first regularly scheduled payroll date following the Effective Date. 

(e)    Full Discharge. You acknowledge and agree that the payment(s) and other benefits provided pursuant to this
paragraph 2 are in full discharge of any and all liabilities and obligations of the Company or any other member of the Company Group to you, monetarily or with respect to employee benefits or otherwise, including but not limited to any and all
obligations arising under that certain Amended and Restated Severance Agreement between you and the Company, dated August 29, 2017 (the “Severance Agreement”), any other alleged written
or oral employment agreement, policy, plan or procedure of the Company or any other member of the Company Group and/or any alleged understanding or arrangement between you and the Company or any other member of the Company Group (other than claims
for accrued and vested benefits under an employee benefit, insurance, or pension plan of the Company or any other member of the Company Group (excluding any severance or similar plan or policy), subject to the terms and conditions of such plan(s)).

 (f)    Taxes. Amounts provided hereunder, including without limitation the Consideration, are subject to
withholding for all applicable taxes, including but not limited to income, employment, and social insurance taxes, as shall be required by law. 

  
 -2- 

 (g)    Options. You hereby acknowledge and agree that, as of the
Separation Date, pursuant to the terms of (A) that certain stock option grant notice, dated March 22, 2016, and (B) that certain stock option grant notice, dated August 8, 2017 (collectively, the “Grant
Agreements”), you will be vested in options to purchase 33,061 shares of the common stock of the Company, in the aggregate, and have not yet vested in options to purchase 45,689 shares of common stock
of the Company, in the aggregate. The stock options granted to you pursuant to the Grant Agreements will remain subject to the terms and conditions of the Grant Agreements and the Company’s 2011 Equity Incentive Plan, as amended and restated on
December 17, 2013, and as further amended from time to time. 
  

	 	3.	Release and Waiver of Claims. 

 (a)    As used in this Agreement,
the term “claims” will include all claims, covenants, warranties, promises, undertakings, actions, suits, causes of action, obligations, debts, accounts, attorneys’ fees, judgments, losses and liabilities, of whatsoever kind or
nature, in law, equity or otherwise. 
 (b)    For and in consideration of the payments and benefits described in
paragraph 2 above, and other good and valuable consideration, you, for and on behalf of yourself and your heirs, administrators, executors and assigns, as of the date hereof, do fully and forever release, remise and discharge each member of the
Company Group and their successors and assigns, together with their respective officers, directors, partners, members, stockholders (including any management company of a stockholder), employees and agents (collectively, and with the Company, the
“Company Parties”) from any and all claims whatsoever up to the date hereof which you had, may have had, or now have against the Company Parties, whether known or unknown, for or by reason of any matter, cause
or thing whatsoever, including any claim arising out of or attributable to your employment or the termination of your employment with the Company or any member of the Company Group, whether for tort, breach of express or implied employment contract,
intentional infliction of emotional distress, wrongful termination, unjust dismissal, defamation, libel or slander, or under any federal, state or local law dealing with discrimination based on age, race, sex, national origin, handicap, religion,
disability or sexual orientation. This release of claims includes, but is not limited to, all claims arising under the Age Discrimination in Employment Act (the “ADEA”), Title VII of the
Civil Rights Act of 1964, the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family and Medical Leave Act, the Equal Pay Act, the Worker Adjustment and Retraining Notification Act, and the Employee Retirement Income Security Act
(excluding claims for accrued, vested benefits under an employee pension benefit plan of the Company Parties), each as may be amended from time to time, and all other federal, state and local laws, the common law and any other purported restriction
on an employer’s right to terminate the employment of employees. You intend the release contained herein to be a general release of any and all claims to the fullest extent permissible by law and for the provisions regarding the release of
claims against the Company Parties to be construed as broadly as possible, and hereby incorporate in this release similar federal, state or other laws, all of which you also hereby expressly waive. 

(c)    You understand and agree that claims or facts in addition to or different from those which are now known or
believed by you to exist may hereafter be discovered, but it is your intention to fully and forever release, remise and discharge all claims which you had, may have had, or now have against the Company Parties, whether known or unknown, suspected or
unsuspected, asserted or unasserted, contingent or noncontingent, without regard to the subsequent discovery or existence of such additional or different facts. Without limiting the foregoing, by signing this Agreement, you expressly waive and
release any provision of law that purports to limit the scope of a general release. 
 (d)    You acknowledge and agree
that as of the date you execute this Agreement, you have no knowledge of any facts or circumstances that give rise or could give rise to any claims under any of the laws listed in the preceding paragraphs. 

  
 -3- 

 (e)    Notwithstanding any provision of this Agreement to the contrary, by
executing this Agreement, you are not releasing any claims relating to: (i) your rights with respect to payment of amounts under this Agreement, (ii) your right to accrued, vested benefits due to terminated employees under any employee
benefit plan of the Company or any other member of the Company Group in which you participated (excluding any severance or similar plan or policy), in accordance with the terms thereof (including your right to elect COBRA continuation coverage),
(iii) any claims that cannot be waived by law or that arise after the date on which you execute this Agreement, or (iv) your right to indemnification, advancement and reimbursement of legal fees and expenses, and directors and officers
liability insurance, as provided by, and in accordance with the terms of, applicable law, the Company’s by-laws or otherwise. 

(f)    You acknowledge and agree that, by virtue of the foregoing, you have waived any relief available to you (including
without limitation, monetary damages, equitable relief and reinstatement) under any of the claims and/or causes of action waived in this paragraph 3. Therefore you agree that you will not accept any award or settlement from any source or proceeding
(including but not limited to any proceeding brought by any other person or by any government agency) with respect to any claim or right waived in this Agreement. 

(g)    You acknowledge and agree that as of the date of this Agreement, you have reported all accidents, injuries or
illnesses relating to or arising from your employment with the Company or the Company Group and that you have not suffered any on-the-job injury or illness for which you
have not yet filed a claim. 
  

	 	4.	Knowing and Voluntary Waiver. You expressly acknowledge and agree that you: 

(a)    are able to read the language, and understand the meaning and effect, of this Agreement; 

(b)    have no physical or mental impairment of any kind that has interfered with your ability to read and understand the
meaning of this Agreement or its terms, and that you are not acting under the influence of any medication, drug or chemical of any type in entering into this Agreement; 

(c)    are specifically agreeing to the terms of the release contained in this Agreement because the Company has agreed
to provide you the Consideration, which the Company has agreed to provide because of your agreement to accept it in full settlement of all possible claims you might have or ever had against the Company Parties, and because of your execution of this
Agreement; 
 (d)    acknowledge that but for your execution of this Agreement, you would not be entitled to the
Consideration; 
 (e)    had or could have the entire Review Period in which to review and consider this Agreement and
the disclosure information provided pursuant to the Older Workers Benefit Protection Act (attached hereto as Exhibit A), and that if you execute this Agreement prior to the expiration of the Review Period, you have voluntarily and knowingly
waived the remainder of the Review Period; 
 (f)    understand that, by entering into this Agreement, you do not waive
rights or claims under the ADEA that may arise after the date you execute this Agreement; 
 (g)    have not relied
upon any representation or statement not set forth in this Agreement made by the Company Group or any of its representatives; 

  
 -4- 

 (h)    were advised to consult with your attorney regarding the terms and
effect of this Agreement; and 
 (i)    have signed this Agreement knowingly and voluntarily. 

5.    No Suit. You represent and warrant that you have not previously filed, and to the maximum extent permitted by
law agree that you will not file, a complaint, charge or lawsuit against any of the Company Parties regarding any of the claims released herein. If, notwithstanding this representation and warranty, you have filed or file such a complaint, charge or
lawsuit, you agree that you shall cause such complaint, charge or lawsuit to be dismissed with prejudice and shall pay any and all costs required in obtaining dismissal of such complaint, charge or lawsuit, including without limitation the
attorneys’ fees of any of the Company Parties against whom you have filed such a complaint, charge, or lawsuit. This paragraph 5 shall not apply, however, to any non-waivable right to file a charge with
the U.S. Equal Employment Opportunity Commission (the “EEOC”) or similar state agency; provided, however, that if the EEOC or similar state agency pursues any claims relating to your employment with the Company
or any member of the Company Group, you agree that you shall not be entitled to recover any monetary damages or any other remedies or benefits as a result and that this Agreement and the Consideration will control as the exclusive remedy and full
settlement of all such claims by you. In addition, I understand that nothing in this Agreement shall be construed to prohibit you from reporting possible violations of law or regulation to any governmental agency or regulatory body or making other
disclosures that are protected under any law or regulation, or from filing a charge with or participating in any investigation or proceeding conducted by any governmental agency or regulatory body. 

6.    No Re-Employment. You hereby agree to waive any and all claims to re-employment with the Company or any other member of the Company Group. You affirmatively agree not to seek further employment with the Company or any other member of the Company Group. You acknowledge that if you re-apply for or seek employment with the Company or any other member of the Company Group, the Company’s or any other member of the Company Group’s refusal to hire you based on this provision will provide
a complete defense to any claims arising from your attempt to apply for employment. 
 7.    Successors and
Assigns. The provisions hereof shall inure to the benefit of your heirs, executors, administrators, legal personal representatives and assigns and shall be binding upon your heirs, executors, administrators, legal personal representatives and
assigns. 
 8.    Severability; Third Party Beneficiaries. If any provision of this Agreement shall be held by
any court of competent jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect. The illegality or unenforceability of such provision, however, shall have no effect upon and shall not impair the
enforceability of any other provision of this Agreement. You acknowledge and agree that each of the Company Parties shall be a third-party beneficiary to the releases set forth in paragraph 3, with full rights to enforce this Agreement and the
matters documented herein. 
 9.    Non-Disparagement. You agree that you
will make no disparaging or defamatory comments regarding any member of the Company Group or their respective current or former directors, officers, employees, members, stockholders (including any management company of a stockholder), or affiliates
in any respect or make any comments concerning any aspect of your relationship with any member of the Company Group or the conduct or events which precipitated your termination of employment from any member of the Company Group. Your obligations
under this paragraph 9 extend to, but are not limited to, text messages, e-mail communications, and comments or postings on blogs, comment boards or social media websites including, but not limited to,
Facebook, Twitter, MySpace or LinkedIn. This paragraph 9 shall not prevent the truthful testimony by any individual or entity in a legal proceeding or pursuant to a governmental, administrative or regulatory investigation. 

  
 -5- 

	 	10.	Cooperation. 

 (a)    You agree that you will provide reasonable
cooperation to the Company and/or any other member of the Company Group and its or their respective counsel in connection with any investigation, administrative proceeding or litigation relating to any matter that occurred during your employment in
which you were involved or of which you have knowledge. The Company agrees to reimburse you for reasonable out-of-pocket expenses incurred at the request of the Company
with respect to your compliance with this paragraph 10(a). You agree to provide information and answer questions as reasonably requested by the Company with respect to any matter on which you worked prior to the Separation Date of which you have
knowledge. 
 (b)    You agree that, in the event you are subpoenaed by any person or entity (including, but not
limited to, any government agency) to give testimony or provide documents (in a deposition, court proceeding or otherwise) which in any way relates to your employment by the Company and/or any other member of the Company Group, you will give prompt
written notice of such request to the Company Representative, in writing to the address specified above, or his successor or designee, and will make no disclosure until the Company and/or the other member of the Company Group has had a reasonable
opportunity to contest the right of the requesting person or entity to such disclosure. 
 11.    Restrictive
Covenants. You hereby acknowledge and agree that the execution of this Agreement does not alter your obligations to any member of the Company Group under any confidentiality, non-compete, non-solicit, invention assignment, or similar agreement or arrangement to which you are a party with any member of the Company Group, including, without limitation, the provisions set forth in that certain Employee Non-Competition, Non-Disclosure and Developments Agreement, signed as of February 16, 2016 (the “Proprietary Rights
Agreement”), which obligations are hereby incorporated into this Agreement and shall survive the termination of your employment with the Company, and you hereby acknowledge, reaffirm and ratify your
continuing obligations to the Company Group pursuant to such agreements or arrangements. You further hereby acknowledge that your continued compliance with these obligations is a condition of your receiving the Consideration described in paragraph 2
above and upon any breach of the Proprietary Rights Agreement, the Company shall be entitled to an immediate refund of any Consideration already received by you. 

12.    Confidentiality. The terms and conditions of this Agreement are and shall be deemed to be confidential, and
shall not be disclosed by you to any person or entity without the prior written consent of the Company, except if required by law, and to your accountants, attorneys and/or immediate family, provided that, to the maximum extent permitted by
applicable law, rule, code or regulation, they agree to maintain the confidentiality of this Agreement. 

13.    Return of Property. You agree that you will promptly return to the Company, and you will retain no copies
of, all property belonging to the Company and/or any other member of the Company Group, including but not limited to all proprietary and/or confidential information and documents (including any copies thereof) in any form belonging to the Company,
cell phone, Blackberry, iPhone or other mobile device, key, credit card, identification card or badge, card access to the building and office floors, employee handbook, laptop, computer or other office equipment, computer user name and password,
disks, data files, thumb drives, and/or voicemail code. If you discover after the Separation Date that you have retained any proprietary and/or confidential information (including, without limitation, proprietary and/or confidential information
contained in any electronic documents or email systems in your possession or control), you agree immediately upon discovery to send an email to the Company Representative and inform the Company of the nature and location of the proprietary and/or
confidential information that you have retained so that the Company may arrange to remove, recover, and/or collect such information. You further acknowledge and agree that the Company shall have no obligation to provide the Consideration referred to
in paragraph 2 above unless and until you have satisfied all your obligations pursuant to this paragraph 13. 

  
 -6- 

 14.     Non-Admission. Nothing
contained in this Agreement will be deemed or construed as an admission of wrongdoing or liability on the part of you or any member of the Company Group. Accordingly, this Agreement may not be admissible in any forum as an admission, but only in an
action to enforce it. 
 15.    Entire Agreement. This Agreement and the Proprietary Rights Agreement constitute
the entire understanding and agreement of the parties hereto regarding the termination of your employment. This Agreement and the Proprietary Rights Agreement supersede all prior negotiations, discussions, correspondence, communications,
understandings and agreements between the parties relating to the subject matter of this Agreement and the Proprietary Rights Agreement. 

16.    Governing Law; Jurisdiction. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS
OF THE STATE OF NEW YORK, APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN THAT STATE, WITHOUT REGARD TO CONFLICT OF LAWS RULES. ANY DISPUTE, CONTROVERSY OR CLAIM BETWEEN YOU AND THE COMPANY ARISING OUT OF THIS AGREEMENT OR THE PROPRIETARY
RIGHTS AGREEMENT SHALL BE RESOLVED BY ARBITRATION ADMINISTERED BY THE AMERICAN ARBITRATION ASSOCIATION (“AAA”) IN ACCORDANCE WITH ITS EMPLOYMENT ARBITRATION RULES INCLUDING THE EMERGENCY INTERIM RELIEF
PROCEDURES OF THE AAA. JUDGMENT ON THE AWARD RENDERED BY THE ARBITRATOR(S) MAY BE ENTERED IN ANY COURT HAVING JURISDICTION THEREOF. THE PLACE OF ARBITRATION SHALL BE NEW YORK, NEW YORK. THE ARBITRATOR(S) MAY GRANT INJUNCTIONS OR OTHER RELIEF IN SUCH
DISPUTE OR CONTROVERSY. THE DECISION OF THE ARBITRATOR(S) SHALL BE FINAL, CONCLUSIVE AND BINDING ON THE PARTIES TO THE ARBITRATION. EXCEPT AS SPECIFICALLY SET FORTH HEREIN, YOU AND THE COMPANY SHALL EACH BEAR THEIR OWN ATTORNEYS’ FEES INCURRED
IN CONNECTION WITH THE ARBITRATION, AND THE ARBITRATOR(S) WILL NOT HAVE AUTHORITY TO BE ENTITLED TO AWARD ATTORNEYS’ FEES UNLESS A STATUTE OR CONTRACT AT ISSUE IN THE DISPUTE AUTHORIZES THE AWARD OF ATTORNEYS’ FEES TO THE PREVAILING PARTY,
IN WHICH CASE THE ARBITRATOR(S) SHALL HAVE THE AUTHORITY TO MAKE AN AWARD OF ATTORNEYS’ FEES AS REQUIRED OR PERMITTED BY APPLICABLE LAW. IF THERE IS A DISPUTE AS TO WHETHER THE COMPANY OR YOU IS THE PREVAILING PARTY IN THE ARBITRATION, THE
ARBITRATOR(S) WILL DECIDE THIS ISSUE. LIABILITY FOR THE FEES AND EXPENSES OF ALL THE ARBITRATORS WITH RESPECT TO THE ARBITRATION SHALL BE EVENLY DIVIDED BETWEEN THE PARTIES TO THE ARBITRATION. THE DETERMINATION RENDERED BY THE ARBITRATOR(S) SHALL
(I) SPECIFY THE FINDING OF FACTS UPON WHICH IT IS BASED AND THE REASONS THEREFOR, AND (II) BE CONCLUSIVE AND BINDING UPON THE PARTIES. NOTWITHSTANDING THE PROVISIONS OF THIS PARAGRAPH, THE COMPANY SHALL NOT BE COMPELLED TO ARBITRATE CLAIMS
ARISING UNDER THE PROPRIETARY RIGHTS AGREEMENT AND MAY INSTITUTE JUDICIAL PROCEEDINGS TO ENFORCE THAT AGREEMENT PURSUANT TO SECTION 14 OF THE PROPRIETARY RIGHTS AGREEMENT. YOU HEREBY AGREE TO SUBMIT ANY AND ALL CLAIMS YOU MAY HAVE AGAINST THE
COMPANY ON AN INDIVIDUAL BASIS. THIS MEANS THAT NO CLAIM (INCLUDING ANY CLAIM RELATED TO TERMS OR CONDITIONS OF YOUR EMPLOYMENT WITH OR COMPENSATION PAID BY THE COMPANY, OR ANY CHANGE IN OR TERMINATION OF YOUR EMPLOYMENT) MAY BE LITIGATED OR
ARBITRATED ON A CLASS OR COLLECTIVE BASIS. YOU ALSO HEREBY WAIVE ANY RIGHT TO SUBMIT, INITIATE, OR PARTICIPATE IN A REPRESENTATIVE CAPACITY OR AS A PLAINTIFF, CLAIMANT, OR MEMBER IN A CLASS ACTION, COLLECTIVE ACTION, OR OTHER REPRESENTATIVE OR JOINT
ACTION AGAINST THE COMPANY, REGARDLESS OF WHETHER THE ACTION IS FILED IN ARBITRATION OR IN A JUDICIAL OR ADMINISTRATIVE FORUM. FURTHERMORE, IF A COURT ORDERS THAT 

  
 -7- 

 
A CLASS, COLLECTIVE, OR OTHER REPRESENTATIVE OR JOINT ACTION SHOULD PROCEED, IN NO EVENT WILL SUCH ACTION PROCEED IN AN ARBITRATION FORUM. CLAIMS MAY NOT BE JOINED OR CONSOLIDATED IN ARBITRATION
WITH DISPUTES BROUGHT BY ANY OTHER INDIVIDUAL(S), UNLESS AGREED TO IN WRITING BY ALL PARTIES. 

17.    Construction. The section or paragraph headings or titles herein are for convenience of reference only and
shall not be deemed a part of this Agreement. The parties hereto acknowledge and agree that each party has reviewed and negotiated the terms and provisions of this Agreement and has had the opportunity to contribute to its revision. Accordingly, the
rule of construction to the effect that ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement. Rather, the terms of this Agreement shall be construed in a reasonable manner to effect the
intentions of both parties hereto and not in favor or against either party. 
 18.    Section 409A. Payments
under this Agreement are intended to be exempt from, or comply with, Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) and this Agreement will be interpreted to achieve this
result. For purposes of this Agreement, each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section 409A. In no event is the Company responsible for any tax or penalty owed by you (other than
for withholding obligations or other obligations applicable to employers, if any, under Section 409A) with respect to payments under this Agreement. 

19.    Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but
all of which shall constitute one and the same instrument, and electronically delivered copies of executed counterparts shall be deemed to be originals for all purposes. 

*            *           
 * 

  
 -8- 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth
below. 
  

			
	MELINTA THERAPEUTICS, INC.
	 

  

	By:
	Title:
	
	 /s/ John Temperato

	John Temperato
	Dated: December 28th, 2017

  

[Signature Page to J. Temperato’s Separation and Release Agreement]

 Exhibit A 

DISCLOSURE INFORMATION PROVIDED PURSUANT TO THE 

OLDER WORKERS BENEFIT PROTECTION ACT 

Confidentiality Provision: The information contained in this Exhibit A is
private and confidential. You may not disclose this information to anyone except your professional advisors provided that, to the maximum extent permitted by applicable law, rule, code or regulation, they agree to maintain the confidentiality of
such information. 
 Eligibility Factors and Time Limitations 

Melinta Therapeutics, Inc., a Delaware corporation (the “Company”) has decided to terminate the
employment of certain employees. Employees who have been notified that they are being terminated are being offered a cash severance payment and benefits in exchange for their signing and not revoking a general release of claims (the
“Release”). The decisional unit in connection with this termination program is Executive Management. 

Employees who have been informed that they are being terminated and who desire to receive the cash severance payment and benefits will have at
least forty-five (45) days from receipt of the Release and this Exhibit A to sign the Release and return it to the Company’s Vice President, Human Resources, Suzie Paulson (the “Company
Representative”) by mail at c/o Melinta Therapeutics, 6320 Quadrangle Drive, Suite 360, Chapel Hill, North Carolina 27517, Attention: Suzie Paulson, or by email at spaulson@melinta. com. The Release
will not become effective or enforceable for a period of seven (7) calendar days following the date of its execution (the “Revocation Period”), during which time an
employee may revoke his or her acceptance of the Release by notifying the Company Representative, in writing, as specified above. To be effective, such revocation must be received by the Company Representative no later than 5:00 p.m. Eastern Time on
the seventh (7th) calendar day following execution of the Release. Provided that the Release is executed and delivered to the Company and not revoked during the Revocation Period, the Release will become effective on the eighth (8th) calendar day
following the date on which the Release is executed and delivered to the Company. 
 Listing of Job Titles and Ages of the Employees
Within the Decisional Unit 
 Who Were Selected For the Termination Program 

 

					
	 Job Title
	  	Age	 
	Acting Chief Executive Officer (Cempra)	  	 	53	 
	Chief Medical Officer (Cempra)	  	 	60	 
	Executive Vice President, CMC (Cempra)	  	 	59	 
	Executive Vice President and Chief Financial Officer (Cempra)	  	 	55	 
	Executive Vice President, Regulatory Affairs (Cempra)	  	 	64	 
	Executive Vice President, Investor Relations and Corporate Communications (Cempra)	  	 	45	 
	Chief Executive Officer (Melinta)	  	 	58	 
	Chief Human Resources and Compliance Officer (Melinta)	  	 	43	 
	Chief Commercial Officer (Melinta)	  	 	53	 

 Listing of Job Titles and Ages of the Employees within the Decisional Unit 

Who Were Not Selected For the Termination Program 
  

					
	 Job Title
	  	Age	 
	Chief Financial Officer (Melinta)	  	 	53	 
	Chief Medical Officer (Melinta)	  	 	61	 
	Chief Scientific Officer (Melinta)	  	 	49	 
	Senior Vice President, Regulatory Affairs & Quality Assurance (Melinta)	  	 	60	 
	Vice President, Program Management and Technical Operations (Melinta)	  	 	56	 
	Senior Vice President, Corporate Development and Strategy (Melinta)	  	 	41	 
	Vice President, Human Resources (Cempra)	  	 	35EX-10.18

 Exhibit 10.18 

AMENDMENT 
 This Amendment
(the “Amendment”) to the License Agreement dated as of December 23, 2005 (the “Agreement”), is effective as of January 6, 2009 (“Amendment Effective Date”), between Eli Lilly and Company, a
corporation organized and existing under the laws of the State of Indiana (“Lilly”), and Targanta Therapeutics Corporation, a corporation organized and existing under the laws of the State of Delaware (“Targanta” or
“Licensee”), successor to InterMune, Inc., a corporation organized and existing under the laws of the State of Delaware (“InterMune”), as purchaser of all rights, title and interest related to oritivancin from
InterMune. 
 WHEREAS, the Parties desire to amend the Agreement to clarify a certain provision thereof; 

NOW, THEREFORE, for good and lawful consideration, the sufficiency of which is acknowledged and agreed, the
Parties, intending to be legally bound, hereby agree as follows: 
 Article 1.         Amendment to
Definition of Product. The last sentence of Section 1.25 of the Agreement is deleted in its entirety. 
 Article 2.
        Effect on Agreement. Except as amended by this Amendment, the Agreement shall remain in full force and effect. After the Amendment Effective Date, every reference in the Agreement to
the “Agreement” shall mean the Agreement as amended by this Amendment. 
 Article 3.
        Counterparts. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which will constitute one and the same instrument. 

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.

  

			
	ELI LILLY AND COMPANY
		
	By:	 	/s/ Gino Santini
		 	  

		 	 Name:  Gino Santini

Title:   Senior Vice President

	
	TARGANTA THERAPEUTICS CORPORATION
		
	By:	 	/s/ Mark Leuchtenberger
		 	  

		 	 Name:  Mark Leuchtenberger

Title:   President & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]